Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Averna, M; Banach, M; Bruckert, E; Drexel, H; Farnier, M; Gaita, D; Magni, P; Marz, W; Masana, L; Silva, AME; Reiner, Z; Ros, E; Vrablik, M; Zambon, A; Zamorano, JL; Stock, JK; Tokgozoglu, LS; Catapano, AL.
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
ATHEROSCLEROSIS. 2021; 325: 99-109. Doi: 10.1016/j.atherosclerosis.2021.03.039
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

März Winfried

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Background and aims: This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in highrisk and very-high-risk patients. Methods: Evidence-based review. Results: Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus. Conclusions: This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment.

Find related publications in this database (Keywords)

2019 ESC

EAS Dyslipidaemia Guidelines

Combination treatment

LDL cholesterol

Triglycerides

Lipid goals

High-risk

© Med Uni Graz • Imprint